Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma

Genes and Development

Volumn 30, Issue 9, 2016, Pages 1020-1033

  Dayton, Talya L ^a   Gocheva, Vasilena ^a   Miller, Kathryn M ^a   Israelsen, William J ^a,b   Bhutkar, Arjun ^a   Clish, Clary B ^c   Davidson, Shawn M ^a   Luengo, Alba ^a   Bronson, Roderick T ^d   Jacks, Tyler ^a   Vander Heiden, Matthew G ^a,e  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

HCC; Metabolism; PKM2

Indexed keywords

BETA CATENIN; BROXURIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLUCOSE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; IDE1 PROTEIN; PKM1 PROTEIN; PKM2 PROTEIN; PROTEIN; PROTEIN P42; PROTEIN P44; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2; CARRIER PROTEIN; ISOPROTEIN; MEMBRANE PROTEIN; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; FATTY LIVER; FOOD INTAKE; GENE EXPRESSION; GERMLINE MUTATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; HEPATIC PROGENITOR CELL; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINE EPITHELIUM CELL; KIDNEY TUBULE CELL; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; LUNG; MALE; METABOLIC DISORDER; METABOLIC DISTRESS; METABOLIC STRESS; MOUSE; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; OXIDATIVE STRESS; PANCREAS ISLET CELL; PARTIAL HEPATECTOMY; PENETRANCE; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; UPREGULATION; WILD TYPE; ANIMAL; CYTOLOGY; ENERGY METABOLISM; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HOMEOSTASIS; LIPID DIET; LIVER TUMOR; MAMMALIAN EMBRYO; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL PROLIFERATION; DIET, HIGH-FAT; EMBRYO, MAMMALIAN; EMBRYONIC DEVELOPMENT; ENERGY METABOLISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; GROWTH AND DEVELOPMENT; HEPATOCYTES; HOMEOSTASIS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; PROTEIN ISOFORMS; THYROID HORMONES;

EID: 84965021899     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.278549.116     Document Type: Article

References (62)

1. Anastasiou D, Yu Y, Israelsen WJ, Jiang J-K, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, et al. 2012. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol 8: 839–847.
2. Baffy G, Brunt EM, Caldwell SH. 2012. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 56: 1384–1391.
3. Barros RPA, Gustafsson J-Å. 2011. Estrogen receptors and the metabolic network. Cell Metab 14: 289–299.
4. Byrne CD, Targher G. 2015. NAFLD: a multisystem disease. J Hepatol 62: S47–S64.
5. Cairns RA, Harris IS, Mak TW. 2011. Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85–95.
6. Chaneton B, Hillmann P, Zheng L, Martin ACL, Maddocks ODK, Chokkathukalam A, Coyle JE, Jankevics A, Holding FP, Vousden KH, et al. 2012. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491: 458–462.
7. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. 2008a. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230–233.
8. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. 2008b. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452: 181–186.
9. Clower CV, Chatterjee D, Wang Z, Cantley LC, Vander Heiden MG, Krainer AR. 2010. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci 107: 1894–1899.
10. David CJ, Chen M, Assanah M, Canoll P, Manley JL. 2010. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463: 364–368.
11. El-Serag HB, Rudolph KL. 2007. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557–2576.
12. El-Serag HB, Tran T, Everhart JE. 2004. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126: 460–468.
13. The ENCODE Project Consortium. 2012. An integrated encyclopedia of DNA elements in the human genome. Nature 489: 57–74.
14. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. 2012. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35: 2402–2411.
15. Farazi PA, DePinho RA. 2006. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674–687.
16. Gao X, Wang H, Yang JJ, Liu X, Liu Z-R. 2012. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell 45: 598–609.
17. Glunde K, Bhujwalla ZM, Ronen SM. 2011. Choline metabolism in malignant transformation. Nat Rev Cancer 11: 835–848.
18. Hacker HJ, Steinberg P, Bannasch P. 1998. Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/DL-ethionine-supplemented diet. Carcinogenesis 19: 99–107.
19. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144: 646–674.
20. Hitosugi T, Kang S, Vander Heiden MG, Chung T-W, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, et al. 2009. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2: ra73.
21. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M, et al. 2004. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113: 1774–1783.
22. Hosios AM, Fiske BP, Gui DY, Vander Heiden MG. 2015. Lack of evidence for PKM2 protein kinase activity. Mol Cell 59: 850–857.
23. Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, et al. 2013. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155: 397–409.
24. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB, Mootha VK. 2012. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336: 1040–1044.
25. Katz Y, Wang ET, Airoldi EM, Burge CB. 2010. Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat Methods 7: 1009–1015.
26. Kaur J. 2014. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014: 943162.
27. Keller KE, Doctor ZM, Dwyer ZW, Lee Y-S. 2014. SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells. Mol Cell 53: 700–709.
28. Knebel B, Haas J, Hartwig S, Jacob S, Köllmer C, Nitzgen U, Muller-Wieland D, Kotzka J. 2012. Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass. PLoS One 7: e31812.
29. Lakso M, Pichel JG, Gorman JR, Sauer B, Okamoto Y, Lee E, Alt FW, Westphal H. 1996. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci 93: 5860–5865.
30. Leng N, Dawson JA, Thomson JA, Ruotti V, Rissman AI, Smits BMG, Haag JD, Gould MN, Stewart RM, Kendziorski C. 2013. EBSeq: an empirical Bayes hierarchical model for inference in RNA-seq experiments. Bioinformatics 29: 1035–1043.
31. Leung C, Yeoh SW, Patrick D, Ket S, Marion K, Gow P, Angus PW. 2015. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol 21: 1189–1196.
32. Li B, Dewey CN. 2011. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics 12: 323.
33. Li S, Sun R, Chen Y, Wei H, Tian Z. 2015. TLR2 limits development of hepatocellular carcinoma by reducing IL18-mediated immunosuppression. Cancer Res 75: 986–995.
34. Lu Z. 2012. Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle progression and tumorigenesis. Chin J Cancer 31: 5–7.
35. Lunt SY, Muralidhar V, Hosios AM, Israelsen WJ, Gui DY, New-house L, Ogrodzinski M, Hecht V, Xu K, Acevedo PNM, et al. 2015. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol Cell 57: 95–107.
36. Luo W, Hu H, Chang R, Zhong J, Knabel M, O’Meally R, Cole RN, Pandey A, Semenza GL. 2011. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145: 732–744.
37. Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H, Zha Z, Liu Y, Li Z, Xu Y, et al. 2011. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 42: 719–730.
38. Marquardt JU, Andersen JB, Thorgeirsson SS. 2015. Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer 15: 653–667.
39. Mauer J, Denson JL, Brüning JC. 2015. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol 36: 92–101.
40. Mazurek S. 2011. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 43: 969–980.
41. Mazurek S, Boschek C, Hugo F. 2005. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15: 300–308.
42. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. 2007. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317: 121–124.
43. Noguchi T, Yamada K, Inoue H, Matsuda T, Tanaka T. 1987. The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. J Biol Chem 262: 14366–14371.
44. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847–860.
45. Patra KC, Hay N. 2014. The pentose phosphate pathway and cancer. Trends Biochem Sci 39: 347–354.
46. Pi-Sunyer X. 2009. The medical risks of obesity. Postgrad Med 121: 21–33.
47. Rahman R, Hammoud GM, Almashhrawi AA, Ahmed KT, Ibdah JA. 2013. Primary hepatocellular carcinoma and metabolic syndrome: an update. World J Gastrointest Oncol 5: 186–194.
48. Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, et al. 2015. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47: 505–511.
49. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 102: 15545–15550.
50. Takenaka M, Yamada K, Lu T, Kang R, Tanaka T, Noguchi T. 1996. Alternative splicing of the pyruvate kinase M gene in a minigene system. Eur J Biochem 235: 366–371.
51. Tong X, Zhao F, Thompson CB. 2009. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev 19: 32–37.
52. Trapnell C, Pachter L, Salzberg SL. 2009. TopHat: discovering splice junctions with RNA-seq. Bioinformatics 25: 1105–1111.
53. Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kastenhuber ER, Weissmueller S, et al. 2014. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell 158: 579–592.
54. Ueki K, Kondo T, Tseng Y-H, Kahn CR. 2004. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci 101: 10422–10427.
55. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM, et al. 2010. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329: 1492–1499.
56. Wang Y-H, Israelsen WJ, Lee D, Yu VWC, Jeanson NT, Clish CB, Cantley LC, Vander Heiden MG, Scadden DT. 2014. Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell 158: 1309–1323.
57. Wong CC-L, Au SL-K, Tse AP-W, Xu IM-J, Lai RK-H, Chiu DK-C, Wei LL, Fan DN-Y, Tsang FH-C, Lo RC-L, et al. 2014. Switching of pyruvate kinase isoform L to m2 promotes metabolic reprogramming in hepatocarcinogenesis. PLoS One 9: e115036.
58. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, Aldape K, Lu Z. 2011. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 480: 118–122.
59. Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L, You MJ, Koh MY, Cote G, Aldape K, et al. 2012a. EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Mol Cell 48: 771–784.
60. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Alfred Yung WK, Lu Z. 2012b. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150: 685–696.
61. Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, Lyssiotis CA, Aldape K, Cantley LC, Lu Z. 2012c. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol 14: 1295–1304.
62. Zhang J, Ma C, Liu Y, Yang G, Jiang Y, Xu C. 2014. Interleukin 18 accelerates the hepatic cell proliferation in rat liver regeneration after partial hepatectomy. Gene 537: 230–237.